Minnesota is considering the legalization of psychedelic drugs. A new bill would create a 23-member “Psychedelic Medicine Task Force,” which would “advise the legislature on the legal, medical, and policy issues associated with the legalization of psychedelic medicine in the state.”
The task force would need to “survey existing studies in the scientific literature on the therapeutic efficacy of psychedelic medicine in the treatment of mental health conditions, including depression, anxiety, post-traumatic stress disorder, and bipolar disorder, and any other mental health conditions and medical conditions for which a psychedelic medicine may provide an effective treatment option.”
The bill lists the psychedelic drugs that could be legalized, including MDMA, psilocybin, mescaline, LSD, bufotenine, DMT, 5-MeO-DMT, 2C-B, ibogaine, salvinorin A, and ketamine. The task force would also need to “assess whether any particular psychedelic is effective in the treatment of any of those conditions, compare that efficacy to conventional drug treatments, and develop a plan that considers the statutory changes necessary for the legalization of psychedelic medicine.”
